MedTrace Logo

Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy

NCT00328302 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2006-05-19

No results posted yet for this study

Summary

The type 1 diabetes patients who were still normoalbuminuric and normotensive, after 17 years duration and a second research kidney biopsy, could enter the double blind treatment study of Atacand or Placebo.

The treatment study continues for five years treatment and ends with a third kidney biopsy.

The study hypothesis is that the effect of ARB during 5 years on the histopathology are more pronounced than the effect on histopathology of placebo.

Conditions

  • Diabetes, Type I

Interventions

DRUG

Candesartan

DRUG

Placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Nina ES Perrin, PhD-student · Karolinska University Hospital, Huddinge, B57, Childrens Hospital, 141 86 Stockholm

  • Ulla B Berg, Professor · Karolinska University Hospital, B57, Childrens Hospital, 141 86 Stockholm, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Completion
2006-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00328302 on ClinicalTrials.gov